New hope for CLL patients: drug combo aims to wipe out remaining cancer cells
NCT ID NCT04501939
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 33 times
Summary
This study tests whether adding cirmtuzumab to the standard drug venetoclax can eliminate remaining leukemia cells in people with chronic lymphocytic leukemia (CLL) who still have detectable disease after taking venetoclax alone. About 5 participants will receive the combination for 6 months. The goal is to see if this approach can make the cancer undetectable and delay the need for future treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UCSD Koman Family Outpatient Pavilion
San Diego, California, 92037, United States
Conditions
Explore the condition pages connected to this study.